Statement of the Third International Exercise-Associated Hyponatremia Consensus Development Conference, Carlsbad, California, 2015

Tamara Hew-Butler, DPM, PhD,* Mitchell H. Rosner, MD,† Sandra Fowkes-Godek, PhD, ATC,‡
Jonathan P. Dugas, PhD,§ Martin D. Hoffman, MD,¶ Douglas P. Lewis, MD,‖
Ronald J. Maughan, PhD,** Kevin C. Miller, PhD, ATC,†† Scott J. Montain, PhD,‡‡
Nancy J. Rehrer, PhD,§§ William O. Roberts, MD, MSc,¶¶ Ian R. Rogers, MBBS,|||
Arthur J. Siegel, MD,*** Kristin J. Stuemple, PhD,††† James M. Winger, MD,‡‡‡ and Joseph G. Verbalis, MD§§§

Key Words: EAH, exercise-associated collapse, hydration


INTRODUCTION

The third International Exercise-Associated Hyponatremia (EAH) Consensus Development Conference convened in Carlsbad, California in February 2015 with a panel of 17 international experts. The delegates represented 4 countries and 9 medical and scientific sub-specialties pertaining to athletic training, exercise physiology, sports medicine, water/sodium metabolism, and body fluid homeostasis. The primary goal of the panel was to review the existing data on EAH and update the 2008 Consensus Statement. This document serves to replace the second International EAH Consensus Development Conference Statement and launch an educational campaign designed to address the morbidity and mortality associated with a preventable and treatable fluid imbalance.

The following statement is a summary of the data synthesized by the 2015 EAH Consensus Panel and represents an evolution of the most current knowledge on EAH. This document will summarize the most current information on the prevalence, etiology, diagnosis, treatment and prevention of EAH for medical personnel, athletes, athletic trainers, and the greater public. The EAH Consensus Panel strove to clearly articulate what we agreed upon, did not agree upon, and did not know, including minority viewpoints that were supported by clinical experience and experimental data. Further updates will be necessary to both: (1) remain current with our understanding and (2) critically assess the effectiveness of our present recommendations. Suggestions for future research and educational strategies to reduce the incidence and prevalence of EAH are provided at the end of the document as well as areas of controversy that remain in this topic.

CONSENSUS METHODOLOGY

The third International Exercise-Associated Hyponatremia Consensus Development Conference utilized National Institutes of Health guidelines, amended for a more holistic approach to fit the needs of both the group and the topic. Twenty-two individuals (17 accepted) were invited to participate in the consensus conference who: (1) have made scientific and/or clinical contributions to the topic of water and sodium homeostasis and/or hyponatremia and (2) represented a specific group (eg, nephrology, endurance medicine, etc.) or had unique topical expertise (eg, cystic fibrosis, muscle cramps, fluid balance, etc.). The present document is intended to serve as the scientific record of the conference with intent to widely disseminate this information to achieve
maximum impact on both current health care practice and future medical research.

The methodology governing the conduct of this consensus development conference is summarized below:


2. These experts presented data on EAH in a day long public session, followed by open question/answer and discussion periods with the audience. The panel members met the following day in a closed session to prepare the consensus statement.

3. Workgroups were created 3 months prior to the February 2015 meeting to update the following EAH target areas: epidemiology, etiology and pathophysiology, diagnosis, treatment, and prevention. Each workgroup was asked to present updated drafts for discussion during the closed session.

4. A systematic, comprehensive and updated literature review was shared by the panel members prior to the February 2015 meeting, using a cloud storage service that was organized into workgroup categories (epidemiology, etiology and pathophysiology, diagnosis, treatment and prevention). All panel members had unlimited access to the cloud storage service and could add digital versions of published manuscripts to the EAH manuscript section at any time.

The panel chairperson (M.H.R) was responsible for monitoring the progress of each work group, directing the closed session and guiding the panel’s deliberations. Using the previous 2 EAH consensus statements as a starting point, each work-group was asked to: (1) incorporate new data into each assigned section and (2) update any outdated information. All recommendations were graded based on clinical strength, using the grading scale described by the American College of Chest Physicians (Table 1).2 Particular emphasis was placed on creating more generalized recommendations so as to prevent and treat EAH across a wider variety of athletic events, rather than the endurance sports focus of the 2 prior EAH Consensus Statements.

### Sponsorship

The travel (except R.J.M. and I.R.R., who supported their own travel), hotel and meal expenses for the participants were funded by CrossFit, Inc (Solana Beach, CA). The open conference was also sponsored by CrossFit, Inc. However, no members from CrossFit, Inc participated in any of the closed discussions or contributed to the development of the consensus guidelines. Furthermore, no members from CrossFit, Inc had access to the consensus document prior to publication.

## RESULTS AND DISCUSSION

### Definition

EAH is used to describe hyponatremia occurring during or up to 24 hours after physical activity. It is defined by a serum, plasma or blood sodium concentration ([Na⁺]) below the normal reference range of the laboratory performing the test. For most laboratories, this is a [Na⁺] less than 135 mmol/L.1 The main determinants of the serum [Na⁺] are the total content of exchangeable body sodium and potassium relative to total body water and thus hyponatremia can result

### TABLE 1. American College of Chest Physicians Classification Scheme for Grading Evidence and Recommendations Utilized in This Statement

<table>
<thead>
<tr>
<th>Grade</th>
<th>Description</th>
<th>Benefits vs Risks and Burdens</th>
<th>Methodological Quality of Supporting Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1A</td>
<td>Strong recommendation, high-quality evidence</td>
<td>Benefits clearly outweigh risks and burdens or vice versa</td>
<td>RCTs without important limitations or overwhelming evidence from observational studies</td>
</tr>
<tr>
<td>1B</td>
<td>Strong recommendation, moderate-quality evidence</td>
<td>Benefits clearly outweigh risks and burdens or vice versa</td>
<td>RCTs with important limitations or exceptionally strong evidence from observational studies</td>
</tr>
<tr>
<td>1C</td>
<td>Strong recommendation, low-quality or very low quality evidence</td>
<td>Benefits clearly outweigh risks and burdens or vice versa</td>
<td>Observational studies or case series</td>
</tr>
<tr>
<td>2A</td>
<td>Weak recommendation, high-quality evidence</td>
<td>Benefits closely balanced with risks and burdens</td>
<td>RCTs without important limitations or overwhelming evidence from observational studies</td>
</tr>
<tr>
<td>2B</td>
<td>Weak recommendation, moderate-quality evidence</td>
<td>Benefits closely balanced with risks and burdens</td>
<td>RCTs with important limitations or exceptionally strong evidence from observational studies</td>
</tr>
<tr>
<td>2C</td>
<td>Weak recommendation, low-quality or very low quality evidence</td>
<td>Uncertainty in the estimates of benefits, risks and burden; benefits, risk and burden may be closely balanced</td>
<td>Observational studies or case series</td>
</tr>
</tbody>
</table>

RCT, randomized controlled trial.
from loss of solutes (sodium, potassium), a relative excess of total body water or a combination of both. However, in most clinical scenarios, the driving force for the development of hyponatremia is a relative excess of total body water. The symptoms associated with EAH depend on both the magnitude of the serum sodium decrease from baseline level along with the rate at which this decrease occurs. Symptomatic EAH can occur if the rate of fall approaches 7% to 10% within 24 hours. Thus, more severe degrees of hyponatremia (typically <125 mmol/L) as well as more modest serum sodium values (in the range of 125-130 mmol/L), that develop over a short period of time, can both be associated with signs and symptoms.

Epidemiology

The vast majority of recreationally active individuals begin endurance races with a blood [Na+] above 135 mmol/L. Based on data pooled from 27 separate studies, encompassing 2262 participants with a verifiable pre-race blood [Na+] measurement, only 0.8% (19/2262) presented with hyponatremia prior to race start. These pooled data represent blood [Na+] measurements collected in 7 countries and between 5 minutes to 72 hours pre-competition. This 0.8% also includes 16 questionable below-normal [Na+] values possibly confounded by fingerstick hemolysis and/or outdated techniques. Thus, baseline (pre-event) hyponatremia in recreational exercisers appears to fall within the expected range for a normal population distribution (1%-2%), and at a frequency well below what has been observed in individuals presenting for non-hyponatremia related clinical treatment situations or in hospitalized patients. We thereby believe that EAH largely develops during or immediately following exercise.

Exercise-associated hyponatremia can present in 2 forms: asymptomatic or symptomatic. Asymptomatic athletes with [Na+] <135 mmol/L have largely been detected by blood samples taken post-exercise from athletes participating in research protocols or obtained for reasons other than suspicion of EAH. Athletes with the symptomatic form of EAH can present with mild, non-specific symptoms (eg, lightheadedness, nausea) but typically present with headache, vomiting, and/or altered mental status (eg, confusion, seizure) resulting from cerebral edema (termed exercise-associated hyponatremic encephalopathy or EAHE) that may or may not be associated with non-cardiogenic pulmonary edema. EAHE is a life-threatening condition that has been observed across a wide variety of activities (Table 2). The incidence of asymptomatic and symptomatic cases of EAH varies widely with regard to type and duration of activity, location of the event, characteristics of the participants (see risk factors) and heat or cold stress during the event.

Epidemiology of Asymptomatic EAH

The reported incidence of asymptomatic EAH has ranged from 0% to 51% immediately post-race. In a study of an ultramarathon, 67% of the participants were hyponatremic (asymptomatic) at some point during the race, but only 27% finished the with serum [Na+] <135 mmol/L (40% self-corrected prior to finishing the event). The highest reported incidence of asymptomatic hyponatremia post-race has been consistently noted in 161-km ultramarathons, in which the reported incidence of EAH has ranged between 5% and 51%. The reported incidence of asymptomatic EAH in Ironman triathlons in different environments has been reported to range from negligible to as high as 18% and 25%. In studies on endurance cyclists the incidence of asymptomatic EAH has ranged from 0% to 12% in a 109-km race. In a 26.4-km swim, 17% of swimmers developed asymptomatic hyponatremia. The reported incidence of asymptomatic EAH has been noted in 33% of premier league UK rugby players following an 80 minutes rugby competition and 70% of elite rowers during a 28-day training camp.

Epidemiology of Symptomatic EAH

Symptomatic EAH is rare and occurs with considerably less frequency than asymptomatic EAH, but complications associated with EAH have led to at least 14 athlete related deaths since 1981. Symptomatic EAH generally occurs as an isolated case or in small clusters during or following endurance events with participants reporting to the race medical facilities or to hospital emergency departments within 24 hours after participation. In general, participants seek treatment for a constellation of symptoms ranging from feeling unwell to convulsions. Clusters of cases have occurred in military training exercises, marathons, Ironman triathlons and ultramarathons. The incidence of symptomatic EAH has been reported to be as high as 23% and 38% of athletes seeking medical care in an Ironman Triathlon and an ultramarathon, respectively, but most endurance events report no cases of symptomatic EAH, especially at the marathon distance and below.

Two studies have examined large compilations of data to help define the incidence of symptomatic and asymptomatic EAH. In the first study of 2135 athletes from 8 endurance events ranging in length from 42.2 to 161 km, the incidence of symptomatic EAH was 1% (compared to 6% with asymptomatic EAH) among study participants. In the

<table>
<thead>
<tr>
<th>TABLE 2. Activities in Which Symptomatic EAH Has Been Reported. Those Activities in Which Known Deaths Have Occurred Are Noted With an Asterisk (*)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endurance competitions (marathon*, canoe race*, ultramarathon, triathlon, swimming)</td>
</tr>
<tr>
<td>Hiking*</td>
</tr>
<tr>
<td>Military exercises*</td>
</tr>
<tr>
<td>Police training*</td>
</tr>
<tr>
<td>American rules football*</td>
</tr>
<tr>
<td>Fraternity hazing*</td>
</tr>
<tr>
<td>Bikram yoga</td>
</tr>
<tr>
<td>Lawn bowling</td>
</tr>
</tbody>
</table>

Copyright © 2015 retained by authors Hew Butler T et al. All rights reserved. www.cjsportmed.com | 305
second study of 669 161-km ultramarathon runners, only one case (0.1% among study participants) of symptomatic EAH presented during the 5-year sampling period (compared to 13% with asymptomatic EAH), but considering the total number of race participants over this time period, the actual incidence of symptomatic EAH was approximately 0.06%.

Symptomatic EAH has also been reported in hikers and military personnel. Symptomatic EAH accounted for 16% of Grand Canyon hikers seeking medical care for exercise-associated collapse or exhaustion from May 31, 1993 through September 31, 1993 providing an estimated incidence rate between 2 and 4 per 100,000 persons. Furthermore, suspected hyponatremia was found to account for 19% of non-fatal suspected heat-related incidents in the Grand Canyon National Park from April through September during 2004 through 2009 hiking seasons. In the US active duty military, the annual incidence rate of hyponatremia from 1999 through 2012 has ranged from ~4 to 13 cases per 100,000 person-years (averaged 6.7 cases per 100 000 person-years). However, this incidence is probably inflated as the data were derived from a medical coded database that does not have a specific designation for EAH and likely includes hyponatremia from both exercise and non-exercise related conditions.

Alarmingly, symptomatic EAH is now being reported in a more diverse set of sporting activities. For instance, symptomatic EAH has been reported in shorter distance endurance competitions, such as a half marathon with slower finishers completing the distance in 2 to 3 hours and a sprint triathlon with slower finishers taking approximately 2 hours to complete. In addition, EAH has been reported in US professional and college American rules football players and has led to the deaths of 3 US high school football players. Symptomatic hyponatremia has also been reported in a 48 year old lawn bowler who was heterozygous for the Delta F508 cystic fibrosis (CF) mutation, although it is unclear if complete genetic analysis for all possible CF mutations was performed. Cases of symptomatic EAH have also been induced in 2 separate laboratory studies involving low intensity exercise conducted in high ambient temperatures. Deaths from symptomatic EAH have occurred in a 25 year old male police officer participating in a 19-km bicycle training ride and at least partially contributed to a case of fraternity hazing involving a male pledge performing calisthenics. It is likely that other cases of symptomatic hyponatremia have either not been recognized or reported.

### Risk Factors

The major risk factors for developing EAH are listed in Table 3. The single most important risk factor is sustained, excessive fluid (water, sports drinks or other hypotonic fluids) intake in volumes greater than loss through sweat, respiratory and renal water excretion so that a positive fluid balance accrues over time. Almost all cases of symptomatic EAH have occurred in individuals who have gained or maintained weight during activities in which some weight loss would represent fluid balance and euhydration.

Body weight losses of <0.75 kg after a standard marathon and <1% after an 80 minutes rugby match have been associated with asymptomatic EAH. All sports beverages are hypotonic to plasma (typical sodium content in sports drinks are approximately 10-38 mmol/L), thus the magnitude of excessive fluid volume ingestion will overwhelm any protective effect of the beverages’ sodium content on maintaining serum [Na⁺].

From a practical standpoint, it is the smaller individuals and those who participate at a slower pace and drink more than sweat losses that are more likely to develop EAH. Although the incidence of women experiencing EAH is greater than that of men, adjusted for BMI and racing time, the apparent sex difference is not statistically significant.

Nonsteroidal anti-inflammatory drugs (NSAIDs) have been implicated as a risk factor in the development of EAH presumably by potentiating the water retention effects of arginine vasopressin (AVP) at the level of the kidney collecting duct. However, data are conflicting and further investigation is necessary to determine whether Nsaid usage— with respect to both classification and dosage—is a risk factor for the development of EAH. The possible pathophysiological contributions of intrinsic renal disease and low solute diets on water retention, high sweat sodium concentrations in extreme environments, and the potentiation of thirst by non-osmotic stimuli during exercise warrant further investigation as secondary risk factors for EAH. Whether common medications that are associated with hyponatremia and the syndrome of inappropriate anti-diuretic hormone secretion (SIADH) in the general population, such as selective serotonin reuptake inhibitors, can potentiate the development of EAH is not known and warrants further investigation.

There is a paucity of evidence suggesting that those developing symptomatic EAH have either been a “salty sweater” or a heterozygous carrier of the cystic fibrosis genotype. Athletes with homozygous CF, however, are at risk for developing hyponatremia as demonstrated by numerous instances when an individual is diagnosed with CF after the development of hyponatremia during prolonged physical exertion or prolonged exposure to high ambient temperatures. As individuals with CF experience a longer lifespan (median predicted survival age in 2012 was 41.1 years) and are encouraged to consider exercise as

### TABLE 3. Risk Factors for the Development of Asymptomatic and Symptomatic EAH

<table>
<thead>
<tr>
<th>Risk Factors for EAH</th>
<th>Risk Factors for Asymptomatic EAH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overdrinking water, sports drinks, and other hypotonic beverages</td>
<td>Overdrinking water, sports drinks, and other hypotonic beverages</td>
</tr>
<tr>
<td>Weight gain during exercise</td>
<td>Weight gain during exercise</td>
</tr>
<tr>
<td>Exercise duration &gt;4 h</td>
<td>Exercise duration &gt;4 h</td>
</tr>
<tr>
<td>Event inexperience or inadequate training</td>
<td>Event inexperience or inadequate training</td>
</tr>
<tr>
<td>Slow running or performance pace</td>
<td>Slow running or performance pace</td>
</tr>
<tr>
<td>High or low body mass index (BMI)</td>
<td>High or low body mass index (BMI)</td>
</tr>
<tr>
<td>Readily available fluids</td>
<td>Readily available fluids</td>
</tr>
</tbody>
</table>

Copyright © 2015 retained by authors Hew Butler T et al. All rights reserved.
one of their therapies,112 this population may be at increased risk for EAH due to the combination of high sweat fluid and sweat [Na+] loss.

**Etiology and Pathophysiology of EAH**

The predominant pathophysiology of EAH, and of most serious medical concern, is dilutional hyponatremia caused by sustained overdrinking and AVP induced impaired water clearance, which overcomes the ability of the kidney to excrete the excess water load. Dilutional hyponatremia is the primary pathophysiological variant of clinically symptomatc EAH and largely (if not exclusively) associated with all reported cases of morbidity and mortality that are listed in Table 2. Dilutional EAH is an acute onset form of hyponatremia, which is now occurring in non-endurance sports, with 3 deaths, recently reported amongst the approximately 7.5 million American high school football player-years from 2008 through the 2014 seasons.63,64,69 These football players were encouraged to ingest copious volumes of hypotonic fluids and sports drinks to prevent or relieve exercise-associated muscle cramps (EAMC),63,64,69 in the belief that EAMC was caused by dehydration and electrolyte imbalance.111 However, experimental114,115 and observational studies speculate that EAH may reflect neurological changes due to fatigue rather than uncompensated water and sodium losses incurred during exercise in some cases. Muscle cramping and tremor have also been associated with overdrinking and hyponatremia in athletes,82,100,118,119 as 161 km ultramarathons; to occur in athletes exercising for longer periods of time (such as ultra-marathons)139 or in hotter Ironman distance triathlons.19,20 The data regarding sodium losses during exercise (as measured during recovery) and their potential contribution to the development of symtomatic hyponatremia in longer and hotter races39 have been consolidated in Table 2 against data collected from relatively shorter and cooler races123,140,141 where fluid overload hyponatremia has been verified. From the standpoint of the clinical literature, hypovolemic hyponatremia reflects a loss of total body exchangeable sodium that manifests as volume depletion.5,6,135,142,143 Hyponatremic EAH would be predicted to occur in athletes exercising for longer periods of time (such as 161 km ultramarathons; >20 hours),19,20,54 and/or in hotter11,19,20,55,108,109 environments and/or with higher sweat sodium losses.99,101 Clinical confirmation of the hypovolemic form of hyponatremia is supported by a spot urine sodium concentration (U[Na+]) below 30 mmol/L,136,137,144 in conjunction with a serum or plasma [Na+] below 135 mmol/L. A spot U[Na+] <30 mmol/L is 100% specific and 80% sensitive for predicting a sustained increase (>5 mmol/L) in serum [Na+] following isotonic saline administration136 in clinical patients. Elevated blood urea nitrogen levels (>20 mg/dL)136,139 and weight loss19,20,55 may also suggest volume depletion as a pathogenic contributor to EAH. However, these biochemical tests are not always available at the point of care and thus clinical assessment (vital signs, weight change, and physical examination) may be the only indication of volume depletion.

**Summary Statement**

Under-replaced sodium losses contribute to serum [Na+] independent of distance (Grade 1A). However, there

---

**Copyright © 2015 retained by authors Hew Butler T et al. All rights reserved.**

**Third EAH Consensus Statement**

**Table 2. Dilutional EAH is an acute onset form of hyponatremia, which is now occurring in non-endurance sports, with 3 deaths, recently reported amongst the approximately 7.5 million American high school football player-years from 2008 through the 2014 seasons.**

**Table 3. Dilutional EAH is an acute onset form of hyponatremia, which is now occurring in non-endurance sports, with 3 deaths, recently reported amongst the approximately 7.5 million American high school football player-years from 2008 through the 2014 seasons.**

**Table 4. Dilutional EAH is an acute onset form of hyponatremia, which is now occurring in non-endurance sports, with 3 deaths, recently reported amongst the approximately 7.5 million American high school football player-years from 2008 through the 2014 seasons.**

**SUMMARY STATEMENT**

The primary etiology and pathophysiological mechanism underlying EAH—and all known fatalities—is the overconsumption of hypotonic fluids relative to exchangeable sodium in likely combination with non-osmotic AVP secretion (Grade 1A).
**TABLE 4.** Comparisons of Sodium and fluid Balance Measured During the Recovery Period After Exercise Demonstrating Race Characteristics and Biochemical Differences Between Fluid Overload Hyponatremia (Irving et al,123 Speedy et al,140 and Speedy et al141) Versus Suspected Hypovolemic Hyponatremia (Owen et al139)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Irving et al123</th>
<th>Speedy et al140</th>
<th>Speedy et al (2 cases)141</th>
<th>Owen et al139</th>
</tr>
</thead>
<tbody>
<tr>
<td>EAH subjects (classification)*</td>
<td>8 (symptomatic)</td>
<td>7 (symptomatic)</td>
<td>2 (asymptomatic)</td>
<td>26 (asymptomatic)</td>
</tr>
<tr>
<td>Peak race temperature (°C)</td>
<td>NR</td>
<td>21</td>
<td>21</td>
<td>33</td>
</tr>
<tr>
<td>Mean exercise duration (h)</td>
<td>&lt;11 (mean NR)</td>
<td>12</td>
<td>13/12 (case 1/case 2)</td>
<td>22</td>
</tr>
<tr>
<td>Monitored recovery time (h)</td>
<td>16</td>
<td>11.6</td>
<td>11.7/13</td>
<td>1</td>
</tr>
<tr>
<td>Presenting ([\text{Na}^+]) (mmol/L)</td>
<td>NR</td>
<td>17† (41 controls)*</td>
<td>NR</td>
<td>15 pre-trial (22.3 post-trial)</td>
</tr>
<tr>
<td>Presenting BUN (mg/dL)</td>
<td>15.5 pre-trial (9.8 post-trial)</td>
<td>NR</td>
<td>NR</td>
<td>31 (pre and post-trial)</td>
</tr>
<tr>
<td>Body sodium retained (mean value);‡</td>
<td>48%</td>
<td>-84 mmol (0 mmol controls)*</td>
<td>34%/0%</td>
<td>96%</td>
</tr>
<tr>
<td>Excess fluid excreted (mL)§</td>
<td>+2953</td>
<td>+1670 (-441 controls)*</td>
<td>+1500/+2500</td>
<td>+20</td>
</tr>
<tr>
<td>Presenting serum [([\text{Na}^+])] (mean ± SD) (mmol/L)</td>
<td>122 ± 2</td>
<td>127 ± 4</td>
<td>131/130</td>
<td>131 ± 3</td>
</tr>
<tr>
<td>Body weight change (post-race – pre-race) (%)</td>
<td>NR</td>
<td>NR</td>
<td>+0.9/+2.5</td>
<td>-2.4 ± 3.1</td>
</tr>
</tbody>
</table>

*EAH data compared with control group of normonatremic triathletes partaking in the same event.  †All but one of these 7 athletes with EAH was released from the hospital with hyponatremia.  ‡This represents the total amount of sodium retained by the body and expressed as a percentage of the total amount of sodium that was administered during the monitored recovery period (sodium deficit/sodium given). In Speedy et al 2000,140 this was expressed as a positive or negative amount (mmol) of sodium administered so that a negative value reflected the amount of sodium retained by the body (\(\text{UNa}^+\) output minus \(\text{Na}^+\) input).  §This represents the amount of fluid excreted (urine volume) during the recovery period compared with the amount of fluid that was administered during the recovery period.  NR, not reported in the manuscript.

There is paucity of data supporting sodium loss as the primary mechanism of symptomatic EAH even in those who exercise for prolonged periods of time and in warm weather (Grade 2C). In these cases, relative over-drinking of hypotonic fluids with sustained non-osmotic AVP secretion is likely involved in the development of symptomatic EAH.

**The Role of Thirst**

Since drinking fluid volume above sweat and urinary losses during and after activity is the main pathophysiological mechanism underlying asymptomatic, symptomatic and fatal cases of EAH, prevention is dependent on drinking less. Thirst should provide adequate stimulus for preventing excess dehydration and markedly reduce the risk of developing EAH in all sports. Physiologically-driven thirst has been defined as a “generalized, deep seated feeling of desire for water”145 and is an evolutionarily conserved, finely tuned, regulatory mechanism serving to protect both plasma osmolality and circulating plasma volume.146 Osmoreceptors located within the circumventricular organs of the brain (highly vascularized structures located around the third and fourth ventricles and characterized by the lack of a blood–brain barrier that are points of communication between the blood, the brain parenchyma, and the cerebral spinal fluid) and baroreceptors located within the aortic arch, carotid sinus and great veins provide “real-time” neural input to higher centers of the brain which continuously and simultaneously coordinate the regulation of both thirst and AVP secretion. Thus, there are physiological sensing mechanisms in place to prompt when to drink and therefore guard against excessive dehydration. Earlier published recommendations to begin drinking before thirst was largely meant for situations where sweating rates were high, above maximal rates of gastric emptying, and dehydration would rapidly accrue over time. Unfortunately, this advice has fostered the misconception that thirst is a poor guide to fluid replacement and has facilitated inadvertent overdrinking and pathological dilutional EAH.

**Clinical Classification and Diagnosis of EAH**

The diagnosis of EAH is made when the blood, serum or plasma \([\text{Na}^+]\) is below the normal reference range of the laboratory performing the test (typically <135 mmol/L) and is associated with typical clinical constellation of symptoms and signs. In our collective experience, EAH is best classified by clinical severity (symptoms) and not the absolute numerical \([\text{Na}^+]\) value to best guide treatment strategies.

**Characteristics of Asymptomatic EAH**

Asymptomatic EAH represents a biochemical finding, diagnosed by blood electrolyte testing for research or unrelated metabolic screening purposes.10,15,18,19,28,30,32,53–59 This group of subjects presents without any discernable symptoms or may have mild, generalized and transient complaints commonly experienced by other participants who do not typically seek medical care following exercise. In normally distributed populations, up to 5% of all athletes tested would fall outside of the normal range for \([\text{Na}^+]\), with half of those (2.5%) falling in the range of asymptomatic EAH values.

**Characteristics of Mild EAH**

Mildly symptomatic EAH typically presents with nonspecific signs and symptoms without clear signs of encephalopathy (Table 5). Athletes with mild EAH may have normal vital signs, may not have any orthostatic hypotension, and the symptoms do not resolve after placing athletes in the Trendelenburg position147 as would be expected with exercise.
TABLE 5. Signs and Symptoms of Mild and Severe (Life-threatening) EAH. Signs and Symptoms Related to Other Conditions Associated With Exercise-Associated Collapse Noted With an Asterisk (*).

<table>
<thead>
<tr>
<th>Symptoms and Signs Associated With Mild EAH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lightheadedness*</td>
</tr>
<tr>
<td>Dizziness*</td>
</tr>
<tr>
<td>Nausea*</td>
</tr>
<tr>
<td>Puffiness</td>
</tr>
<tr>
<td>Body weight gain from baseline</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Symptoms and Signs Associated With Severe EAH and EAHE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vomiting*</td>
</tr>
<tr>
<td>Headache*</td>
</tr>
<tr>
<td>Altered mental status* (confusion, disorientation, agitation, delirium, feelings of “impending doom,” obtundation)</td>
</tr>
<tr>
<td>Phantom running</td>
</tr>
<tr>
<td>Seizure*</td>
</tr>
<tr>
<td>Coma*</td>
</tr>
<tr>
<td>Signs of impending brain herniation (decorticate posturing, mydriasis)</td>
</tr>
<tr>
<td>Dyspnea (non-cardiogenic pulmonary edema)</td>
</tr>
<tr>
<td>Frothy sputum (non-cardiogenic pulmonary edema)</td>
</tr>
</tbody>
</table>

associated postural hypotension.\textsuperscript{148} The clinical symptoms of mild symptomatic EAH are not specific or sensitive, but should raise the index of suspicion for EAH and necessitate a low threshold for [Na⁺] measurement, as athletes can rapidly progress from mild symptoms to severe and life-threatening EAHE (Table 5).

EAH must be differentiated from other causes of collapse that may present with similar signs and symptoms including exertional heat illness,\textsuperscript{73} acute mountain sickness,\textsuperscript{39} hyponatremia,\textsuperscript{149,150} and exercise associated postural hypotension.\textsuperscript{148} It is important for medical staff to perform a rapid history and physical examination to help determine the etiology of these nonspecific symptoms. However, any clinical suspicion of EAH should lead to prompt measurement of [Na⁺], if possible. It is common for athletes with EAH to maintain or gain weight during exercise.\textsuperscript{58,71,72} However, EAH in the presence of weight loss has been documented in ultra-endurance races in the heat.\textsuperscript{19,20,55,59} Thus, the presence of weight loss does not necessarily exclude EAH. Weight gain or weight maintenance associated with any symptoms listed in Table 5 is an indication to measure the athlete’s [Na⁺] in order to confirm or exclude the diagnosis of EAH or to consider empiric treatment if on-site [Na⁺] cannot be measured, such as in remote settings.\textsuperscript{52,118,151}

Characteristics of Severe EAH (EAHE)

Severe symptomatic EAH is characterized by neurological signs and symptoms due to cerebral edema that occur when water flows along the osmotic gradient from the extracellular fluid into the intracellular compartment (Table 3).\textsuperscript{38–52,152} Severe symptomatic EAH may\textsuperscript{38–48} or may not\textsuperscript{49,52} be accompanied by the respiratory distress of CNS-triggered non-cardiogenic pulmonary edema (Table 5). EAHE is a life threatening condition that requires urgent intervention and should be evaluated with an immediate [Na⁺] measurement if available.

SUMMARY STATEMENT

EAH can present with a wide range of symptoms ranging from nonspecific mild complaints to severe encephalopathy. The severity of symptoms and not the absolute value of the [Na⁺] should guide the choice of therapy (Grade 1A). Rapid determination of [Na⁺] is critical in confirming clinical suspicion but may not always be available.

Treatment of EAH

Any athlete exhibiting signs or symptoms consistent with acute hyponatremia (Table 5) should be screened for EAH. The capacity for onsite [Na⁺] analysis is optimal for management of EAH and is recommended for any large-scale endurance event. However, this capability is not always practical or possible (eg, small or remote events).\textsuperscript{118,151} Treatment should be based on the degree of neurological impairment, not simply the [Na⁺] level\textsuperscript{5,6}; as brain edema is dependent upon both the magnitude and rate of fall of [Na⁺] not just the lowest level reached, as stated previously. The following treatment protocols are recommended for EAH and EAHE based on either [Na⁺] measurement and clinic assessment or clinical assessment alone if [Na⁺] measurement is not available.

Onsite Treatment of Asymptomatic EAH Found Via [Na⁺] Measurement

Asymptomatic hyponatremia is not normally detected unless an athlete has blood electrolyte concentrations tested for some other reason.\textsuperscript{10,15,18,19,28,36,53–59} In athletes with this incidental biochemical diagnosis, oral or intravenous hypotonic fluid intake should be restricted until the onset of urination (which suggest that AVP levels have fallen and that the urine is likely dilute) to reduce the risk of further decreasing [Na⁺] with continued AVP-mediated water retention.\textsuperscript{5,6,120} Furthermore, isotonic intravenous fluids should be administered with great caution or withheld until urination as, in the setting of elevated AVP levels and a concentrated urine, these fluids may lower the [Na⁺]\textsuperscript{53} or delay recovery.\textsuperscript{91,151,154}

Although there is no compelling reason to actively treat asymptomatic EAH, it is clinically appropriate to administer oral hypertonic saline solutions (HTS), to reduce the risk of progression to symptomatic hyponatremia.\textsuperscript{39,155} This is particularly relevant for those with a [Na⁺] <130 mmol/L. Upon departure from the event site, athletes with asymptomatic EAH should be advised to seek urgent medical attention if any neurologic signs or symptoms of EAH develop within 24 hours after event finish, since delayed-onset symptomatic EAH may frequently occur.\textsuperscript{40,42,46,52,72,80,82,91,100,122,156} Ideally, an athlete with asymptomatic EAH should have a companion upon discharge from the medical area to observe the affected athlete for signs and symptoms of evolving EAH, since the neurological impairments associated with EAH may limit the athlete’s ability to accurately self-assess his or her status.
SUMMARY STATEMENT

The major clinical relevance of asymptomatic EAH lies in its potential for asymptomatic athletes to quickly transition and progress into symptomatic stages if hypotonic fluids are given intravenously or ingested (Grade 1C). Thus, in patients identified with EAH, hypotonic or isotonic fluids should be withheld until urination is documented (Grade 1C).

Onsite Treatment of Symptomatic EAH Found Via [Na+] Measurement

Severe EAH (EAHE)

Acute severely symptomatic hyponatremia is a rapidly progressing, life threatening emergency that requires immediate administration of IV hypertonic saline (HTS) (such as 3% sodium chloride). Because EAHE is an acute rather than chronic process, athletes presenting with symptomatic hyponatremia can and should be treated with HTS as there is no risk of osmotic demyelination after exposure to HTS, but there is grave risk of brain herniation and non-cardiogenic pulmonary edema if HTS is not administered.

Any athlete with EAHE associated with signs or symptoms of encephalopathy should be immediately treated with an IV bolus or infusion of HTS to acutely reduce brain edema, with additional IV boluses administered until there is clinical improvement (Table 6). The dose and route of HTS administration should be based upon the severity of clinical symptoms and the available HTS formulations, as discussed in Table 6. Numerous case reports and case series have validated the efficacy and safety use of IV HTS administration in symptomatic EAHE, with one runner receiving 950 mL of 3% over a 7-hour period without complications and another swimmer receiving 40 mL of 20% HTS without complication.

In the event that an athlete presents with symptoms of severe, life-threatening encephalopathy (e.g., seizures, coma, or signs of impending brain herniation) it is acceptable and highly recommended to administer the first bolus of HTS before [Na+] is measured. Confirmed symptomatic dilutional (euvoletic or hypervolemic) EAHE is a contraindication to the administration of IV hypotonic fluids, lactated Ringzer’s, or isotonic (normal) saline, all of which can worsen the degree of hyponatremia or delay recovery.

The efficacy of IV HTS as the definitive treatment of acute hyponatremic encephalopathy has been validated extensively in both hospital and field settings since it was first utilized successfully in 1938. This treatment is based on the capacity of an IV HTS bolus to increase the serum [Na+] 2 to 5 mmol/L, resulting in a concomitant decrease of intracranial pressure and improvement in symptoms. This approach does not pose any substantial danger to the patient, because osmotic demyelination syndrome has not been associated with either the rapid correction of acute hyponatremia (i.e., <48 hours duration) in clinical or exercise settings or with the limited increase in [Na+] produced by a single bolus of HT. Also, of note, if the athlete was wrongly assumed to have EAHE, the administration of HTS in small boluses is not associated with any negative consequences and serves as an excellent volume expander.

The goal of this therapy is to stabilize the athlete for transfer to an advanced medical care facility for further evaluation, monitoring and treatment. Ideally, the athlete should be transported with knowledgeable event medical personnel able to maintain the same level of care en route and to ensure that the treatment is not interrupted for evaluation such as computerized tomography (CT) imaging of the brain or treatments that may worsen hyponatremia, such as administration of hypotonic fluids, lactated Ringer’s, or isotonic (normal) saline. The diagnosis of EAH or EAHE must be communicated to the receiving physician upon transfer of care.

<table>
<thead>
<tr>
<th>TABLE 6. Recommended Treatment for Both Mild and Severe (Life-threatening) Symptomatic EAH in Field or in the Hospital</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of Mild EAH</td>
</tr>
<tr>
<td>Observation (restrict hypotonic and isotonic fluids until urinating freely)</td>
</tr>
<tr>
<td>Administration of intravenous HTS (see below for severe symptomaticatology)</td>
</tr>
<tr>
<td>Administration of oral HTS:</td>
</tr>
<tr>
<td>Concentrated bouillon (4 bouillon cubes in 125 mL, ½ cup, of water)</td>
</tr>
<tr>
<td>3% NaCl (100 mL), preferably with the addition of a flavoring (e.g., Crystal Light, Kool Aid)</td>
</tr>
<tr>
<td>Equivalent volumes of other solutions of high sodium concentration (e.g., 3%-9%)</td>
</tr>
<tr>
<td>Treatment of Severe EAH</td>
</tr>
<tr>
<td>Administration of intravenous HTS:</td>
</tr>
<tr>
<td>3% NaCl (100 mL), repeated twice if there is no clinical improvement (10 min intervals have been recommended, but this should be determined by the clinical judgment of the treating physician)</td>
</tr>
<tr>
<td>Comparable amounts of more concentrated Na+-containing solutions (e.g., 10 mL of 20% NaCl; 50 mL of 8.4% NaHCO3) may be used as an alternative to 3% NaCl</td>
</tr>
<tr>
<td>In some situations (e.g., more severe encephalopathic symptomaticatology such as seizures, coma or signs of impending brain herniation) it may be appropriate to administer larger HTS boluses initially rather than waiting to assess clinical improvement after repeated smaller boluses</td>
</tr>
</tbody>
</table>

HTS, hypertonic saline.
studies, and may offer practical advantages in some settings (eg, IV HTS or IV access is not available). In contrast to athletes with severe EAH, those with milder symptoms may be discharged from onsite medical care once symptoms have resolved and spontaneous urination has occurred. Repeat measurement of [Na+] is generally not required unless the patient has persistent symptoms after the initial treatment. As is recommended for asymptomatic EAH, upon departure from the event site athletes should be advised to seek urgent medical attention if any signs or symptoms of EAH develop after discharge and ideally should have a companion capable of monitoring for signs and symptoms of which the athlete may not be aware.

**SUMMARY STATEMENT**

Athletes presenting with mild symptoms associated with EAH can be treated with an IV bolus of HTS (Grade 1B), oral hypertonic saline fluids or observation until the onset of urination as dictated by clinical symptoms (Grade 2B).

**Onsite Treatment of EAH Suspected Clinically but Unable to Confirm Via [Na+] Measurement**

The situation may arise where EAH is strongly suspected based on the clinical evaluation of the athlete (ie, history and physical examination showing neurological symptoms or signs of EAH; Table 3) but [Na+] cannot be determined, such as in a remote setting. In this situation empiric treatment is justified using the same treatment recommendations described above for EAH documented with a [Na+] (Table 6). This empiric approach can be lifesaving and is unlikely to do harm, since: (1) the additional small increase in serum osmolality from a single bolus of HTS will not significantly worsen the neurological status and (2) a bolus of HTS will expand the intravascular volume by increasing the serum [Na+], partially reducing any hypovolemic component of the hyponatremia.

**In Hospital Treatment of Symptomatic EAH**

Athletes presenting to a hospital or medical facility, whether primarily or as a transfer from the event site, with signs or symptoms of hyponatremia will require immediate measurement of electrolytes and should be treated as described above without delay once EAH is confirmed (Table 6). If symptomatic EAH persists or worsens following the initial intervention with IV HTS, current treatment guidelines for acute symptomatic hyponatremia should be instituted and the patient managed in an intensive or critical care setting with care provided or guided by a specialist familiar with this life threatening condition.

**SUMMARY STATEMENT**

Athletes presenting to a medical facility with EAH should be treated as per other settings (Grade 1C). However, diagnostic testing in these scenarios should not delay potentially life-saving therapy with HTS (Grade 1C).
The safest individualized hydration strategy before, during and immediately following exercise is to drink palatable fluids when thirsty (Figure). Marathon runners with hypernatremia report “thirstiness” as a physiologically expected symptom while a weak but statistically significant relationship has been demonstrated between thirst ratings and plasma [Na⁺] immediately following a 161 km race. Studies verify that participants allowed free access.

### TABLE 7. Thirteen Studies Representing 41 Cases of Symptomatic EAH Which Provided Comment on Drinking Plan or Motivation for Chosen Drinking Behaviors [*Case Reports Involving Multiple Subjects: Total Number Subjects (Number of Female/Male Subjects)]

<table>
<thead>
<tr>
<th>Study</th>
<th>Subjects Age (yo), Sex (♀♂), Activity</th>
<th>Serum [Na⁺] mmol/L (Initial or Range)</th>
<th>Symptomatic EAH With Drinking Above Thirst (Comments From Report)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frizzell et al122</td>
<td>24, ♂/45, ♂, Ultra-runners</td>
<td>123/118</td>
<td>Runners as a group are taught to “push fluids”</td>
</tr>
<tr>
<td>Armstrong et al84</td>
<td>21, ♂, Lab subject</td>
<td>122</td>
<td>…voluntarily consumed this large volume of fluid because he believed that drinking water copiously would decrease his risk of heat illness</td>
</tr>
<tr>
<td>Herfel et al41</td>
<td>22, ♂, Football player</td>
<td>121</td>
<td>He was diagnosed with muscle cramps secondary to dehydration. Therefore, five liters (L) of 0.45% normal saline in 5% dextrose was administered intravenously along with 3L of liquids by mouth over a five hour period</td>
</tr>
<tr>
<td>Reynolds et al161</td>
<td>*6 (♀♂/2♂♂), Soldiers</td>
<td>118-134</td>
<td>…consuming large volumes of water as “protection against becoming a heat casualty” predisposed these troops to the physical impairment that they intended to avoid</td>
</tr>
<tr>
<td>Backer et al73</td>
<td>*7 (♀♂/1♂♂), Hikers</td>
<td>109-127</td>
<td>Most patients diagnosed as having hyponatremia have a distinct history of high fluid intake…</td>
</tr>
<tr>
<td>Garigan and Ristedt45</td>
<td>18, ♂, Soldier</td>
<td>121</td>
<td>…unlike heat exhaustion patients, few of our hyponatremic patients were thirsty when evaluated, perhaps because they drank more fluids and were hyperhydrated</td>
</tr>
<tr>
<td>Hew et al86</td>
<td>*21 (♀♂/8♀♂), Marathon runners</td>
<td>117-134</td>
<td>…complained of thirst, drank 3 quarts then vomited… told to drink 1 quart every 30 minutes. With encouragement by unit members, he consumed 10 quarts of water during the next 90 minutes</td>
</tr>
<tr>
<td>Dimeff40</td>
<td>27, ♂, Football player</td>
<td>116</td>
<td>…with encouragement by unit members</td>
</tr>
<tr>
<td>Hew-Butler et al8</td>
<td>41, ♂, Ironman triathlete</td>
<td>132 (nadir)</td>
<td>Advice given to runners was “drink until your urine is clear” and “do not wait until you are thirsty to drink”</td>
</tr>
<tr>
<td>Draper et al99</td>
<td>37, ♀, Marathon runner</td>
<td>117</td>
<td>…complained of feeling ill… encouraged to consume sports drinks</td>
</tr>
<tr>
<td>Hew-Butler et al8</td>
<td>41, ♂, Ironman triathlete</td>
<td>132 (nadir)</td>
<td>…Admits to drinking 2-3 gallons water every day because he had been taught that “water is the best replacement fluid” and because that is what he was advised to do growing up in Texas</td>
</tr>
<tr>
<td>Draper et al99</td>
<td>37, ♀, Marathon runner</td>
<td>117</td>
<td>Subject reports he was never thirsty, but drank to “stay ahead of thirst”</td>
</tr>
<tr>
<td>Rothwell and Rosengren118</td>
<td>43, ♂, Hiker</td>
<td>107</td>
<td>…she followed a strategy (as advised by fellow experienced marathon runners) to begin the race “well-hydrated” (drinking greater volumes than her thirst dictated)</td>
</tr>
<tr>
<td>Coler et al151</td>
<td>85, ♂, Hiker</td>
<td>120</td>
<td>…warnings were issued over the public address system at the race start relating to ensuring a high intake of fluids was maintained</td>
</tr>
<tr>
<td>Rogers et al91</td>
<td>46, ♀, Swimmer</td>
<td>118</td>
<td>…complained of abdominal pains and leg cramps for 24 hours leading up to collapse</td>
</tr>
</tbody>
</table>

The safest individualized hydration strategy before, during and immediately following exercise is to drink palatable fluids when thirsty (Figure). Marathon runners with hypernatremia report “thirstiness” as a physiologically expected symptom while a weak but statistically significant relationship has been demonstrated between thirst ratings and plasma [Na⁺] immediately following a 161 km race. Studies verify that participants allowed free access.
to fluids during treadmill walking in the heat\textsuperscript{169} or running 30 km under different ambient conditions\textsuperscript{170} maintain plasma osmolality by drinking to thirst. Moreover, the cues to drink provided by osmolality and blood volume persist in both hot\textsuperscript{101} and cold\textsuperscript{171} environments. Thus, drinking to thirst will, in most cases, prevent both dilutional EAH and performance decrements due to excessive dehydration.\textsuperscript{10} Potential exceptions to this fluid replacement strategy are thirst stimulated by confounding oral variables such as dry mouth (xerostomia),\textsuperscript{102,172} genetic influences,\textsuperscript{103}

FIGURE. Primary recommended fluid intake strategy to prevent symptomatic EAH.

<table>
<thead>
<tr>
<th>TABLE 8. Four Case Reports Reporting Symptomatic EAH While Drinking Either ad libitum (First 2 Cases) or in Response to Thirst (Second 2 Cases)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study</strong></td>
</tr>
<tr>
<td>Baker et al\textsuperscript{85}</td>
</tr>
<tr>
<td>Hew-Butler\textsuperscript{134}</td>
</tr>
<tr>
<td>Khodaee et al\textsuperscript{100}</td>
</tr>
<tr>
<td>Hoffman et al\textsuperscript{72}</td>
</tr>
</tbody>
</table>
known discrepancies between drinking “ad libitum” versus drinking according to the dictates of thirst, the excessive sodium intake and/or other non-osmotic or hypovolemic factors that are yet to be determined and require further investigation (Table 8).

**SUMMARY STATEMENT**

Given that excessive fluid consumption is a primary etiologic factor in EAH, using the innate thirst mechanism to guide fluid consumption is a strategy that should limit drinking in excess and developing hyponatremia while providing sufficient fluid to prevent excessive dehydration (Grade 1C).

**Additional Strategies to Prevent EAH**

**Sodium Supplementation**

When fluid intake matches or even slightly exceeds sweat losses, the ingestion of sodium-containing sports drinks can attenuate the rate of fall of [Na⁺] over the course of 2 hours of continuous or intermittent cycling and ~4 hours of running. However, it is critical to emphasize that sodium containing sports drinks, which are hypotonic, will not prevent EAH in athletes who overdrink during exercise, as all sports drinks have a significantly lower [Na⁺] (10-38 mmol/L) than serum (~140 mmol/L). The dilutional effect of volume excess overwhelms any positive effect of sodium and electrolytes in sports drinks. Therefore, while modest salt replacement is likely not harmful and has been associated with significant increases or no change in serum [Na⁺] during competitive field events it will be of modest to no benefit in situations where excess fluids are being consumed. The potential detrimental effects of excessive sodium supplementation are not clear.

**SUMMARY STATEMENT**

Sodium supplementation is a strategy for attenuating sodium concentration reductions that can develop when fluid intakes approximate sweat losses during prolonged exercise but cannot prevent EAH in the setting of a persistent excessive fluid intake that produces fluid overload (Grade 1C).

**Education and Event Management Efforts**

Athlete and support team educational strategies should be instituted to improve knowledge of safe hydration practices and reduce the overemphasis on high fluid intakes. For example, an education program for an Ironman triathlon advising athletes of the risks incurred by overdrinking coupled with decreasing the number of fluid stations to limit the fluid availability reduced the incidence of EAH. Dissemination of appropriate drinking advice alone has also been shown to reduce the incidence of EAH in a 90 km footrace.

Past studies have demonstrated that cycling fluid stations placed 20 km apart in an Ironman triathlon and running fluid stations placed 5 km apart in a standard marathon have reduced or prevented EAH. However, this proposed strategy and its effect on the incidence of EAH needs further study to determine the optimal number and spacing of fluid stations in different terrains and ambient temperatures. Furthermore, alternative strategies will be needed in settings where EAH has been noted but either aid stations are not provided or in situations where drinks are freely available and/or athletes transport their own fluids.

Athletes who seek more quantitative guidance are encouraged to weigh themselves before and after training to assess their sweating rates and fluid replacement needs. Some weight loss associated with activity will be unrelated to fluid status as non-water mass is lost as energy is expended (~0.23-0.24 g/kcal) and is increased with increasing duration and intensity of exercise. The presence of weight gain is positive indicator that fluid intake has been in excess of fluid losses and water overload is present.

**SUMMARY STATEMENT**

Educational efforts regarding the risks of overhydration should be encouraged and disseminated widely to athletes, coaches, and event management personnel (Grade 1C). These efforts should include all sporting events where EAH has been encountered. Event management strategies such as limiting access to fluids may be of benefit, but require broader study.

**Dissemination of Advice for Prevention and Treatment of EAH**

**Athletes, Coaches, Parents**

Educational strategies and programs are needed that effectively communicate to coaches, athletes, and parents rational fluid replacement, avoidance of overconsuming fluids (water, sports drinks or other hypotonic fluids), to recognize the signs and symptoms of EAH, and to understand the critical need for immediate medical attention for suspected casualties. Athletes, coaches and parents must be alert to the risks of excessive fluid consumption and understand that high fluid intakes will not necessarily prevent exercise-associated maladies such as muscle cramps or exertional heat stroke.

**On-site Medical Professionals (Medics, Paramedics, Emergency Medical Technicians, Athletic Trainers, Physiotherapists, and Others)**

The educational strategies for on-site medical personnel must address the circumstances (during or following events or practices during acclimatization), identification, evaluation and management of EAH and EAHE, and emphasize that the life-threatening nature of these rare conditions require immediate intervention. The pathophysiology of EAH and the drinking behaviours involved in the evolution of EAH must be clearly recognized. It should be stressed that: (1) EAH is caused primarily by the consumption of hypotonic fluid in excess of sweat and urinary losses and (2) excessive fluid intake (water, sports drinks or other hypotonic beverages) may not prevent muscle cramps or exertional heatstroke and in rare cases may even be associatively. On-site personnel must understand that oral fluid intake and IV fluid infusion of hypotonic and isotonic fluids is contraindicated in all suspected cases.
of EAH and rapid transfer to a hospital is necessary. The potential life-saving role of HTS requires wide-spread education and should be considered the equivalent of automatic external defibrillators and ice/cold water immersion in the “first aid” of sudden cardiac arrest and exertional heat stroke, respectively.

**Team Physicians and Medical Directors of Athletic Events**

Team physicians and medical directors of athletic events should be involved in all decisions regarding medical management including overseeing medical protocols, medical supplies/equipment, strategies for fluid replacement that optimize safe hydration practices, placement of fluid stations, and the use of intravenous rehydration. Important athletic event decisions include spacing and placement of fluid stations, distribution of fluid replacement advice to athletes, and training of the aid station personnel and spectators. Drinking advice distributed to participants by sponsors should be reviewed by and approved by the event medical team to avoid conflict with the official race educational information.

Team physicians and event medical directors should ideally have onsite point of care [Na⁺] analysis available and hypertonic saline on hand for management of EAH and EAHE. The event organizer/medical director should be in contact with the local emergency medical services to ensure that transportation to an advanced care medical facility is available during events with high risk for EAH (Table 2).

A record of EAH cases should be kept, including follow up and outcome, to aid in planning for future events and to establish both incidence and prevalence for different events.

**Emergency Medical Services and Hospitals**

Prior to the race or athletic event, the medical team should establish a relationship with the local emergency response and transport teams, medical facilities and emergency department physicians. This may include specific collaborative education programs aimed at all of these groups and pre-event checklists to ensure that the appropriate course of action is taken and the needed supplies are available in the emergency room when an athlete arrives in extremis.

**SUMMARY STATEMENT**

Prevention of EAH requires broad educational programs with consistent messages that stress the importance of appropriate hydration practices, recognition of EAH and proper therapy (Grade 1C).

**Controversies in EAH**

**Hypovolemic Hyponatremia**

It is unclear whether the hypovolemic variant of EAH has medical consequences. At present, we have apparent evidence of hypovolemic hyponatremia developing over the course of ultra-endurance event, but we lack data regarding: (1) the relative contribution of solute deficits versus fluid status and (2) whether or not the hypovolemic component is somehow compromising the afflicted individual. Most of the contributions of sweat and urinary sodium losses are negligible to the overall pathogenesis of EAH with the possible exception of volume depleted athletes with low serum sodium levels. Thermoregulatory sweat is hypotonic, with sweat sodium concentrations ranging between 10 and 70 mmol/L, which are well below the normal (isotonic) range of values for serum [Na⁺] (135-145 mmol/L). While there will always be some contribution of sodium loss to the pathogenesis of EAH—which will vary significantly in magnitude depending on: exercise intensity, exercise duration, body size, and relative ambient temperature—it is not clear whether or not sweat sodium losses alone can account for the changes in hypovolemic hyponatremia in athletes. The potential role of urinary sodium losses from exercise-induced brain natriuretic peptide secretion contributing to EAH is also unclear.

There are 3 distinct groups of athletes that demonstrate extreme sodium conservation which may increase the susceptibility towards the development of hypovolemic hyponatremia: (1) runners participating in 161 km races under hot conditions, (2) Ironman triathletes participating in hot and humid Ironman triathlons and (3) football players during the first week of training camp. These 3 groups would hypothetically be at greater risk for developing the hypovolemic variant of EAH from more vigorous and sustained sweating (and associated sweat sodium and potassium losses) coupled with an inability to eat sufficient foods to offset the sodium and potassium losses. Football players may also lack adequate adaptations to heat stress, at the onset of pre-season training, which would prevent excessive sweat sodium losses with repeated exposure.

**Treatment of Hypovolemic Hyponatremia**

Participants with suspected hypovolemic EAH and developing signs of encephalopathy would be best treated initially with an IV HTS bolus to reverse intracerebral edema and expand the intravascular volume. The initial bolus of HTS can be followed by IV 0.9% saline, if neurological symptoms improve. At least one panel member has successfully treated athletes who were clinically volume depleted, with measures of [Na⁺] as low as 124 mmol/L, with IV normal saline infusion. As in all cases of EAH, it would be harmful to treat with hypotonic IV solutions.

**Clinical Importance of Asymptomatic EAH**

The clinical relevance of the asymptomatic form of EAH continues to be disputed. We agree that the main clinical relevance of asymptomatic EAH lays in the potential for asymptomatic athletes to transition to symptomatic EAH with the continued ingestion of hypotonic fluids. Moreover, symptomatic EAH can rapidly progress to life-threatening symptomatic hyponatremia if large volumes of hypotonic fluids are ingested after identification of asymptomatic EAH is present or are administered intravenously during recovery from exercise.

**SUGGESTIONS FOR FUTURE RESEARCH**

Prospective and controlled clinical trials should be performed both in the laboratory and in the field to best
determine optimal preventative and therapeutic strategies. Some of the remaining issues for study include:

- Examining nutritional requirements and/or role of diet on the risk for EAH.
- Examining tolerance versus risk for various forms (tablets vs solution) and amounts of sodium supplementation on health, performance and natremia status.
- Gathering evidence with regards to the success of the “drink to thirst” strategy on prevention and/or reduction of the incidence of EAH in athletic events.
- Determining if the development of EAH increases the risk for recurrence and/or long-term health problems.
- Identifying genetic markers which may predispose individuals to developing EAH.
- Additional research is necessary to understand whether individuals consuming NSAIDS are at heightened risk of developing EAH.
- Investigating the efficacy of alternative treatments for non-life threatening EAH, including oral hypertonic sodium solutions, sodium tablets and vasopressin receptor antagonists.
- Clarifying the etiology behind the apparent hypovolemic variant of EAH and the potential for pathophysiological consequences.
- Evaluating the variability in \([\text{Na}^+]\) in the days leading up to the event, at event start and during the event.
- Evaluating the variability in body weight in the days leading up to the event and at event start.

### SUMMARY OF RECOMMENDATIONS

**Etiology of EAH**

1. The primary etiology and pathophysiological mechanism underlying EAH—and all known fatalities—is the overconsumption of hypertonic fluids relative to exchangeable sodium in likely combination with non-osmotic AVP secretion (Grade 1A).
2. Under-replaced sodium losses contribute to serum \([\text{Na}^+]\) independent of distance (Grade 1A). However, there is paucity of data supporting sodium loss as the primary mechanism of symptomatic EAH even in those who exercise for prolonged periods of time and in warm weather (Grade 2C). In these cases, relative over-drinking of hypertonic fluids with sustained non-osmotic AVP secretion is likely involved in the development of symptomatic EAH.

**Clinical Classification and Diagnosis of EAH**

1. EAH can present with a wide range of symptoms ranging from nonspecific mild complaints to severe encephalopathy. The severity of symptoms and not the absolute value of the \([\text{Na}^+]\) should guide the choice of therapy (Grade 1A). Rapid determination of \([\text{Na}^+]\) is critical in confirming clinical suspicion but may not always be available.

**Treatment of EAH**

1. The major clinical relevance of asymptomatic EAH lies in its potential for asymptomatic athletes to quickly transition progression into symptomatic stages if hypertonic fluids are given intravenously or ingested (Grade 1C). Thus, in patients identified with EAH, hypotonic or isotonic fluids should be withheld until urination is documented (Grade 1C).
2. For those athletes presenting with signs and symptoms consistent with EAH, emergent intravenous treatment therapy with hypertonic saline is indicated and should not be delayed pending laboratory measurement or other diagnostic testing (Grade 1B).
3. Athletes presenting with mild symptoms associated with EAH can be treated with an IV bolus of HTS (Grade 1B), oral hypertonic saline fluids or observation until the onset of urination as dictated by clinical symptoms (Grade 2B).
4. Athletes presenting to a medical facility with EAH should be treated as per other settings (Grade 1C). However, diagnostic testing in these scenarios should not delay potentially life-saving therapy with HTS (Grade 1C).

**Prevention of EAH**

1. Given that excessive fluid consumption is a primary etiologic factor in EAH, using the innate thirst mechanism to guide fluid consumption is a strategy that should limit drinking in excess and developing hyponatremia while providing sufficient fluid to prevent excessive dehydration (Grade 1C).
2. Prevention of EAH requires broad educational programs with consistent messages that stress the importance of appropriate hydration practices, recognition of EAH and proper therapy (Grade 1C).

### ACKNOWLEDGMENTS

Dr. Dale Benjamin Speedy presented at the conference and had input into the initial drafts, but withdrew authorship before the final version. We thank CrossFit, Inc for support of this consensus conference.

### REFERENCES

318

Hew-Butler et al

Clin J Sport Med • Volume 25, Number 4, July 2015

www.cjsportmed.com

Copyright © 2015 retained by authors Hew Butler T et al. All rights reserved.


